SCHEMBL2089012

SCHEMBL2089012

Sc1cc(Cl)c(Cl)c(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
HPGD P15428 5/20 0.47
HSD17B10 Q99714 5/20 0.47
CYP3A4 P08684 3/20 0.47
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
AHR P35869 7/20 0.41
TSHR P16473 4/20 0.40
CASP1 P29466 1/20 0.40
CYP1B1 Q16678 1/20 0.39
TRPV4 Q9HBA0 1/20 0.39
HSP90AA1 P07900 1/20 0.36
MAPK1 P28482 1/20 0.36
HTR3E A5X5Y0 1/20 0.36
HTR3B O95264 1/20 0.36
HTR3A P46098 1/20 0.36
HTR3D Q70Z44 1/20 0.36
HTR3C Q8WXA8 1/20 0.36
IDO1 P14902 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185761 0.79 TRPV4 (0.39) ALDH1A1CYP3A4AHRTRPV4MAPK1
SCHEMBL15211566 0.74 GAA (0.39) ALDH1A1CYP3A4HSP90AA1MAPK1
SCHEMBL9509241 0.73 HSD17B10 (0.58) ALDH1A1HPGDHSD17B10CYP3A4CRHBP
SCHEMBL13236551 0.73 TRPV4 (0.36) TRPV4IDO1
SCHEMBL23699480 0.72 TSHR (0.47) ALDH1A1HPGDHSD17B10CYP3A4TSHR
SCHEMBL10538480 0.72 AHR (0.65) ALDH1A1HPGDHSD17B10CYP3A4CRHBP
SCHEMBL48326 0.71 CYP3A4 (0.56) ALDH1A1HPGDHSD17B10CYP3A4CRHBP
Benzenethiol SCHEMBL27855954 0.70 ALDH1A1 (0.57) ALDH1A1HPGDHSD17B10CYP3A4CRHBP
SCHEMBL358001 0.69 ALDH1A1 (1.00) ALDH1A1HPGDHSD17B10CYP3A4CRHBP
SCHEMBL2906064 0.69 AHR (0.67) ALDH1A1HPGDHSD17B10CYP3A4CRHBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11919921-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2024-03-05 US disclosed
US-11827666-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2023-11-28 US disclosed
US-11827666-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2023-11-28 US disclosed
CN-109563120-B alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2022-12-02 CN disclosed
US-20220289783-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2022-09-15 US disclosed
US-11377464-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2022-07-05 US disclosed
US-11377464-B2 Galactoside inhibitor of galectins GALECTO BIOTECH AB (DK) 2022-07-05 US disclosed
CN-113621005-A alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2021-11-09 CN disclosed
US-20210284678-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS GALECTO BIOTECH AB (DK) 2021-09-16 US disclosed
CN-107406478-B alpha-D-galactoside inhibitors of galectins 格莱克特生物技术公司 2021-07-27 CN disclosed
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1300399-B1 PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME KOWA CO (JP) 2007-08-22 EP disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
US-6664256-B1 Interleukin- 1 beta inhibitors KOWA CO., LTD. (JP) 2003-12-16 US disclosed
EP-1300399-A1 PHENYLPYRIDAZINE DERIVATIVES AND DRUGS CONTAINING THE SAME Kowa Co., Ltd. (JP) 2003-04-09 EP disclosed
US-4055652-A 1-[β(R-thio)phenethyl]imidazoles and derivatives thereof SYNTEX (U.S.A.) INC. (US) 1977-10-25 US disclosed
US-4036975-A FUNGICIDES, BACTERICIDES AND ANTIPROTOZOA AGENTS XYNTEX (U.S.A) INC. (US) 1977-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827666-B2 Galactoside inhibitor of galectins LGALS1, LGALS2, LGALS3 ALDH1A1 772/4885HPGD 2202/4885HSD17B10 2421/4885
US-11377464-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 ALDH1A1 1974/4885HPGD 2838/4885HSD17B10 3578/4885
US-11919921-B2 Galactoside inhibitor of galectins LGALS3, LGALS1, LGALS2 ALDH1A1 1974/4885HPGD 2838/4885HSD17B10 3578/4885
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ALDH1A1 412/4885HPGD 1951/4885HSD17B10 363/4885
US-20220289783-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS1, LGALS3, LGALS2 ALDH1A1 1785/4885HPGD 3116/4885HSD17B10 3212/4885
US-20210284678-A1 NOVEL GALACTOSIDE INHIBITOR OF GALECTINS LGALS1, LGALS2, LGALS3BP ALDH1A1 981/4885HPGD 2855/4885HSD17B10 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.